Adage Capital Partners’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-141,000
| Closed | -$10.7M | – | 1054 |
|
|
2025
Q4 | $10.7M | Sell |
141,000
-150,000
| -52% | -$10.9M | 0.02% | 650 |
|
|
2025
Q3 | $17.9M | Sell |
291,000
-314,905
| -52% | -$16.4M | 0.03% | 500 |
|
|
2025
Q2 | $29.6M | Buy |
605,905
+10,905
| +2% | +$518K | 0.05% | 357 |
|
|
2025
Q1 | $30.3M | Buy |
595,000
+288,244
| +94% | +$14.4M | 0.06% | 326 |
|
|
2024
Q4 | $13.8M | Buy |
306,756
+56,756
| +23% | +$2.43M | 0.02% | 531 |
|
|
2024
Q3 | $9.28M | Sell |
250,000
-50,000
| -17% | -$1.67M | 0.02% | 619 |
|
|
2024
Q2 | $9.17M | Sell |
300,000
-970,000
| -76% | -$31.4M | 0.02% | 619 |
|
|
2024
Q1 | $36.9M | Buy |
1,270,000
+377,762
| +42% | +$10.6M | 0.07% | 302 |
|
|
2023
Q4 | $24.6M | Buy |
892,238
+742,238
| +495% | +$17M | 0.05% | 366 |
|
|
2023
Q3 | $3.36M | Sell |
150,000
-528,247
| -78% | -$19.6M | 0.01% | 704 |
|
|
2023
Q2 | $27.6M | Sell |
678,247
-1,168,753
| -63% | -$57.2M | 0.06% | 326 |
|
|
2023
Q1 | $89.5M | Buy |
+1,847,000
| New | +$84.4M | 0.2% | 123 |
|
|
2022
Q4 | – | Sell |
-15,000
| Closed | -$753K | – | 1035 |
|
|
2022
Q3 | $753K | Sell |
15,000
-45,000
| -75% | -$2.2M | ﹤0.01% | 900 |
|
|
2022
Q2 | $2.4M | Sell |
60,000
-70,000
| -54% | -$2.45M | 0.01% | 870 |
|
|
2022
Q1 | $4.85M | Buy |
+130,000
| New | +$5.01M | 0.01% | 835 |
|
|
2019
Q1 | – | Sell |
-12,000
| Closed | -$412K | – | 728 |
|
|
2018
Q4 | $412K | Sell |
12,000
-75,000
| -86% | -$2.7M | ﹤0.01% | 696 |
|
|
2018
Q3 | $4.09M | Buy |
+87,000
| New | +$3.6M | 0.01% | 650 |
|
|
2016
Q3 | – | Sell |
-350,000
| Closed | -$2.46M | – | 722 |
|
|
2016
Q2 | $2.46M | Buy |
350,000
+100,000
| +40% | +$733K | 0.01% | 633 |
|
|
2016
Q1 | $1.61M | Buy |
+250,000
| New | +$4.34M | ﹤0.01% | 649 |
|
|
2015
Q1 | – | Sell |
-125,000
| Closed | -$6.47M | – | 746 |
|
|
2014
Q4 | $6.47M | Sell |
125,000
-175,000
| -58% | -$7.7M | 0.02% | 595 |
|
|
2014
Q3 | $13.2M | Sell |
300,000
-126,666
| -30% | -$3.96M | 0.03% | 483 |
|
|
2014
Q2 | $11.2M | Buy |
+426,666
| New | +$9.13M | 0.03% | 509 |
|
|
2014
Q1 | – | Sell |
-576,666
| Closed | -$9.79M | – | 726 |
|
|
2013
Q4 | $9.79M | Buy |
576,666
+416,666
| +260% | +$7.32M | 0.03% | 518 |
|
|
2013
Q3 | $3.43M | Buy |
+160,000
| New | +$2.78M | 0.01% | 616 |
|
Other funds holding PTCT
RI
AC
Adage Capital Partners's PTCT Position: Q1 2026 in Review
Adage Capital Partners sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 141,000 shares — an estimated $10.7M sold.
Adage Capital Partners first reported a position in PTCT in Q3 2013 and held it in 24 quarters. The position peaked at $89.5M in Q1 2023. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Adage Capital Partners reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
- Adage Capital Partners sold 141,000 PTC Therapeutics shares in Q1 2026, an estimated $10.7M.
- Adage Capital Partners first reported a position in PTC Therapeutics in Q3 2013 and held it in 24 quarters.
- Adage Capital Partners's PTC Therapeutics position peaked at $89.5M in Q1 2023.
- 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.